Epiodyne was founded to develop breakthrough small molecule medicines based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke. Together with our founders and with the highly experienced medicinal chemistry team at R2M Pharma (https://www.linkedin.com/company/r2m-pharma/), we are using quantitative pharmacological and behavioral techniques to translate our insights into novel medicines for patients with opioid use disorder (OUD). We are backed by a syndicate of experienced biotech VCs and located in the Bay Area.
There is no investment information
No recent news or press coverage available for Epiodyne.
We care about your data, and we'd love to use cookies make your experience better.